Endocrinology · Pulmonology · 2 h ago
Higher HbA1c Linked to Mortality in Cystic Fibrosis–Related Diabetes
A UK Cystic Fibrosis Registry study of 4,477 people with cystic fibrosis–related diabetes found that higher interval mean HbA1c was associated with higher mortality. The adjusted mortality rate ratio was 1.93 for HbA1c above 69 mmol/mol compared with 42 mmol/mol or lower.
- Registry analysis included 4,477 people with CF-related diabetes.
- There were 758 deaths over 31,311 person-years.
- Mortality rose across higher HbA1c categories.
- Association does not show that lowering HbA1c reduces mortality.
Researchers used UK Cystic Fibrosis Registry data to assess the association between updated interval mean HbA1c and mortality among people with cystic fibrosis–related diabetes. Poisson regression models adjusted mortality rate ratios for age, calendar year, sex, BMI, pulmonary function and use of CFTR modulators.
The analysis included 4,477 individuals and 31,311 person-years of follow-up; 758 participants died. Mortality increased progressively across HbA1c categories. Compared with HbA1c of 42 mmol/mol or lower, adjusted mortality rate ratios were 1.41 (95% CI 1.15–1.73) for above 42 to 53 mmol/mol, 1.66 (1.33–2.07) for above 53 to 69 mmol/mol, and 1.93 (1.53–2.43) for above 69 mmol/mol.
The findings establish an adjusted association, not evidence that lowering HbA1c reduces mortality. The supplied abstract does not provide further details on study limitations or whether residual confounding was assessed.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Diabetes Care: Long-term Glycemia and Risk of Death in Cystic Fibrosis–Related Diabetes: A UK Cystic Fibrosis Registry Study ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.